In the lab: six lab innovations scientists hope will end malaria
The Gates’ aim to eradicate malaria by 2040 by doubling funding over the next decade to support the roll out of new products to tackle rising drug resistance against the disease.
Their goal of permanently ending transmission of the disease between humans and mosquitoes is more ambitious than the Sustainable Development Goal of ending epidemic levels of malaria by 2030.
They are also supporting a push to create the world’s first vaccine against a parasite.
Six innovations scientists are working on are:
* New insecticides: Mosquitoes are becoming resistant to insecticides used to spray inside homes and in bed nets.
“There is no current insecticide that doesn’t show insect-resistance at the moment,” said Jed Stone, a spokesman for the UK-based Innovative Vector Control Consortium (IVCC).
Indoor spraying of walls with insecticide — which was used to wipe out malaria in the United States in the 1940s — has fallen by 40 percent since 2012 due to resistance to older products and the high cost of newer ones.
The IVCC is developing three new insecticides for use in indoor sprays and bed nets that kill insecticide-resistant mosquitoes.
“The insecticides are virtually ready but it will take about five years to finally develop them,” Stone said, adding that this largely involves registration with regulators.
* A single-dose cure: A pill that would wipe out all parasites in the body could be available by 2019, the Gates Foundation says.
Human trials of one candidate are planned following successful tests on mice, published in 2015.
Existing drugs have to be taken for three days with the risk that people do not finish their medication, contributing to the development of drug-resistant malaria.
They also only kill parasites at the asexual-stage where they cause fever but not at the sexual-stage where they are picked up by mosquitoes in blood.
* Insecticide-treated wall liners: Scientists hope insecticide-treated wall liners, which look like wallpaper, will be more effective than spraying people’s homes with insecticide every three to eight months. The wall liners kill mosquitoes that rest on them and can last for three years.
Tanzania’s National Institute for Medical Research is testing wall liners in 6,000 homes to see if they protect people from malaria. Results will be published in 2017.
* Insecticide-embedded clothing: American soldiers have been wearing combat uniforms treated with permethrin, a synthetic insecticide, since 2010 to protect them against insect-borne diseases.
The U.S. government’s Walter Reed Army Institute of Research will test the effectiveness of treated combat uniforms and repellent creams in July on Tanzanian soldiers who often catch malaria when working at night as peacekeepers.
* A vaccine: This is a big one, given vaccines success in eliminating smallpox, polio and measles in many countries.
More than 30 malaria vaccines are under development.
The Mosquirix vaccine, discovered in 1987, is a decade ahead of other candidates but, to date, it only halves the number of bouts of malaria young children suffer.
The World Health Organization is seeking funding for a pilot program to administer Mosquirix to 400,000 to 800,000 African children. The results will be used to make a decision on whether to use the vaccine more widely.
* GM mosquitoes: Scientists have genetically modified (GM) mosquitoes by adding genes that block the development of the malaria parasite inside the insect and prevent it from being transmitted to people.
Scientists have also genetically modified mosquitoes to make them infertile, so that they die out. But many are cautious about the unforeseen consequences of this.
“When people imagine a malaria end game scenario, GM mosquito technology would be incredibly powerful because it doesn’t rely on a robust health system in order to go in and disrupt transmission of the parasite,” said Martin Edlund, chief executive of Malaria No More, referring to war-torn countries like South Sudan.
The International Center for Journalists and Malaria No More provided a travel grant for this report